Onconova Therapeutics (NASDAQ: ONTX) Decreased to Hold at Zacks Investment Research

Onconova (NASDAQ: ONTX) was devalued by Zacks.com  from a “purchase” score to a “hold” score in a research note issued to capitalists on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical firm. It concentrates on discovering as well as developing tiny molecule medication candidates to treat cancer. The Business‘s items under various phases of advancement consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 as well as Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Several other equities research experts also just recently talked about the business. Noble Financial editioned a “get” ranking and also released a $11.00 cost purpose on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their cost target on Onconova Therapeutics from $29.00 to $12.00 and also set a “purchase” rating on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and a twelve month high of $28.95. Business has a 50 day moving ordinary price of $2.90 as well as a two-hundred day relocating average price of $4.16. The company has a market cap of $46.76 million, a P/E proportion of -1.82 as well as a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly earnings outcomes on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) profits per share for the quarter, covering experts’ agreement price quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% as well as an unfavorable net margin of 8,294.27%. The firm had revenue of $0.06 million throughout the quarter, compared to the agreement price quote of $0.06 million. Throughout the same quarter in the previous year, the company posted ($ 0.45) EPS. En masse, research analysts forecast that Onconova Therapeutics will upload -1.18 EPS for the current year.

A variety of hedge funds have lately dealt shares of ONTX. GSA Funding Partners LLP acquired a brand-new placement in Onconova Therapeutics during the third quarter worth $922,000. Hudson Bay Resources Management LP acquired a brand-new position in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC acquired a new position in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC acquired a new position in shares of Onconova Therapeutics in the third quarter worth $493,000. Finally, Dimensional Fund Advisors LP purchased a brand-new position in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds and also various other institutional investors possess 13.36% of the company’s stock.

Concerning Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which takes part in the identification and also growth of oncology therapeutics. It concentrates on finding and also creating small particle medicine candidates to treat cancer. The business was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 as well as is headquartered in Newtown, PA

. Obtain a totally free copy of the Zacks research record on Onconova Therapeutics (ONTX).

For more details about research offerings from Zacks Investment Research, go to Zacks.com.

This instantaneous information alert was created by narrative science modern technology and monetary information from Market in order to provide viewers with the fastest as well as most accurate coverage. This tale was examined by Market’s editorial group prior to publication. 



Prior to you take into consideration Onconova Therapeutics, you’ll want to hear this.

Market keeps an eye on Wall Street’s top-rated as well as ideal performing research analysts and the stocks they advise to their clients each day. Market has identified the five stocks that cover experts are quietly murmuring to their customers to buy now prior to the wider market catches on … and also Onconova Therapeutics had not been on the list.

While Onconova Therapeutics currently has a “Buy” ranking among experts, top-rated analysts think these five stocks are better buys.